13F Holdings
中文EN

BIOM BIOMOLECULAR LIFE HOLDINGS, INC.

Pharmaceutical Preparations · OTC · SEC CIK 1091326 · Fiscal year ends 12/31

Financial factors as of 2015-09-30 (2015Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY51.4%
TTM EPS YoY91.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-381.4%
ROIC (approx.)—
Asset turnover0.00x

Leverage & solvency

Liabilities / assets431.7%
Debt / equity—
Current ratio0.01x
Interest coverage-1.32x

Cash quality & payout

Operating cash flow / net income0.20x
Accruals ratio-305.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20142014-12-31FY20132013-12-31
Income statement
Revenue$0$0
R&D expense$865,702$808,517
SG&A expense$911,355$1.35M
Operating income-$4.14M-$3.91M
Interest expense$2.76M$1.08M
Income tax$0$0
Net income-$6.19M-$7.42M
EBITDA-$4.14M-$3.91M
EPS (basic)-0.22-0.91
EPS (diluted)-0.22-0.91
Weighted avg. shares (diluted)27.63M8.19M
Balance sheet
Cash & equivalents$33,992$713,892
Current assets$246,266$789,386
PP&E, net$0$0
Intangibles$1.08M$1.08M
Total assets$1.32M$1.87M
Current liabilities$5.83M$6.33M
Total liabilities$5.16M$5.64M
Shareholders' equity-$4.51M-$4.47M
Shares outstanding46.22M17.46M
Cash flow statement
Operating cash flow-$1.91M-$1.04M
Capital expenditure$0$0
Free cash flow-$1.91M-$1.04M
Investing cash flow$0$0
Financing cash flow$1.23M$1.75M
Depreciation & amortization$0$0
Stock-based compensation$0$0

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.